Incyte's (INCY) 989 is First-in-Class, Has Broad Clinical Utility - Citizens

December 9, 2025 5:12 AM EST Send to a Friend
Citizens analyst Reni J. Benjamin reiterated a Market Perform rating and {REMOVEPT} price target on Incyte (NASDAQ: INCY).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login